Protocol Ledger

NCT05915026 · Phase III · COMPLETED

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Interventional Phase III clinical trial protocol NCT05915026 sponsored by Bayer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-16 Enrollment: 105 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05915026
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05915026
Protocol FieldVerified Registry Value
NCT IdentifierNCT05915026
Consolidated Lead SponsorBayer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment105 participants (ACTUAL)
Registered Start Date2023-08-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05915026
Hospital Research SiteLocationSite Profile
Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
ZhuJiang Hospital of Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI